CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to MNMD

MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))

Phase 2
Mind Medicine (MindMed) Inc. (MNMD)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Aug '27
MNMDPhase 2

MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) Phase 2 Est. Readout

MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Aug 2027~STALE
CT.gov
00%
Competitive Landscape

1 competitor in Autism Spectrum Disorder

View Full Landscape
Drug Information

Target Indication

Autism Spectrum Disorder

Clinical Trial

NCT07303907

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.